Sanofi uses creative camouflage in physician-targeted campaign for potential cancer biomarker
As Sanofi studies a new kind of cancer drug, it’s prepping physicians for its potential biomarker expression.
Sanofi’s tusamitamab ravtansine is an antibody-drug conjugate (ADC) that targets CEACAM5-expressing tumors and is currently in a Phase III study to treat advanced non-small cell lung cancer. A companion diagnostic test is also under development, said François-Xavier Etaix, Sanofi’s global brand lead for CEACAM5, in an email interview.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.